Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis
2021-005573-12Phase 2Active
- Sponsor
- LEO Pharma
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoint: Pharmacokinetic parameters of tralokinumab after multiple subcutaneous administrations. Started Mar 2022; status: active.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-005573-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005573-12.